Position in XERS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$15,512,919
+$4,435,859 QoQ
Shares Held
1,958,702
+2.6% QoQ
Ownership
1.07%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
#13
of 238 holders
Holding Since
Mar 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XERS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026ARMISTICE CAPITAL, LLC holds $319,058,775 across 7 Drug Manufacturers - Specialty & Generic names. XERS ranks #5 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SUPN |
Supernus Pharmaceuticals, Inc.
|
2,646,201 | $123,074,808 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
535,838 | $90,310,136 | |
| 3 | IRWD |
Ironwood Pharmaceuticals Inc
|
13,932,000 | $58,653,720 | |
| 4 | PBH |
Prestige Consumer Healthcare Inc.
|
336,000 | $15,882,720 | |
| 5 | XERS |
Xeris Biopharma Holdings, Inc.
This page
|
1,958,702 | $15,512,919 | |
| 6 | EOLS |
Evolus, Inc.
|
1,436,000 | $9,965,840 | |
| 7 | CTOR |
Citius Oncology, Inc.
|
8,705,589 | $5,658,632 |
All Filings in XERS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,512,919 | 1,958,702 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $11,077,060 | 1,909,838 | Shares | Sole | 2026-05-15 | |
| 2022-09-30 | $3,906,912 | 2,504,431 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $8,968,960 | 5,824,000 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $19,110,382 | 7,464,993 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||